D25.0 D25.1
Conditions
Interventions
Group 1: The patient is evaluated interdisciplinarily by the treating gynecologist with the request for treatment of a complaint-causing finding (uterine fibroma) and is called for an indication for r
Sponsors
Klinikum der Universität München, Campus Großhadern
Eligibility
Sex/Gender
Female
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Age of at least 18 years. 2. Current creatinine 3. Indication for local ablative therapy by means of HIFU 4. Accessibility of the fibroid / fibroids with HIFU 5. Funaki Type I-II 6. Signed declaration of consent with compliance incl. Follow-up treatment with compliance including follow-up treatment 7. Size of fibroid <12 cm 8. Exclusion of a leiomyosarcoma 9. Signed declaration of consent
Exclusion criteria
Exclusion criteria: 1. Taking Ulipristalacetat (Esmya) over the past 6 months 2. General MRI contraindications (pacemakers, metal parts) 3. contrast agent allergy 4. Significantly reduced general condition 5. Massive obesity (BMI> 40) 6. Patients with mental / psychiatric disorders 7. pregnancy 8. intrauterine Device 9. Funaki Type III-IV 10. Pedunculated serous fibroid 11. Detection of a Leiomyosarcoma
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Achievement of the final follow-up (12 months) or performing any additional myoma therapy (e.g., myomactomy, hysterectomy, or Radiofrequency Ablation (RFA)) | — |
Countries
Germany
Contacts
Public ContactChristel Besseler
Klinik und Poliklinik für Radiologie Klinikum der Universität München Campus Großhadern
Outcome results
None listed